Revenue +2.0% YoY. Profit margin 2.68%. Yet UNH has rallied 29.8% over the past year and sits 5% below its 52-week high, with restnvest's Timing scoring 3 of 3 supportive. 26 analysts: 85.29% Buy, 13.73% Hold, 0.98% Sell. Average target $448.17 vs current $383.30.
UnitedHealth operates across the full vertical of US healthcare — insurance through UnitedHealthcare, pharmacy benefits through OptumRx, data through OptumInsight, and direct care through OptumHealth. Few competitors can replicate that integration. The trade-off is exposure: revenue and earnings are tied directly to US healthcare policy — Medicare Advantage rates, Medicaid reimbursement, and the regulatory environment for pharmacy benefit managers.
UnitedHealth converts scale into earnings by aggregating purchasing power on the pharmacy side, using proprietary data to manage medical cost ratios on the insurance side, and reinvesting in Optum's care-delivery footprint. Trailing-twelve-month net income of $12.04 billion on $449.7 billion of revenue produces a 2.68% profit margin — narrow but typical of managed care, where most premium dollars pay claims. ROE of 12.18% (used as an ROIC proxy) captures restnvest's 'High Returns, Limited Reinvestment' pattern.
Y = price target. X = days remaining on call (negative = past expected hit window). Bubble size = Anachart Performance Score. Dashed vertical = the expected-hit boundary.
Chart shows 5 of 26 covering analysts. See all on Anachart →
UnitedHealth is the rare case where the analyst community and the price chart agree, and restnvest's fundamental signal disagrees with both. The professional consensus is 85.29% Buy, every recent visible note raised its target, and the chart shows a stock 5% off its 52-week high with all three Timing signals supportive. Against that, restnvest reads the Financial Scorecard at 1 of 4 strong and the Valuation Scorecard at 1 of 4 sensible. The business produces $12 billion of trailing net income on $449.7 billion of revenue — that is real scale and real profitability — but the 2.68% profit margin leaves narrow room for things to disappoint, and the P/E of 28.8x is what investors are willing to pay for a margin recovery that has not yet shown up in the earnings line. Berkshire Hathaway's exit from the position under Greg Abel is one data point; the 85% Buy consensus is another; both are visible to the market. For a long-term investor weighing the UNH financial health alongside the analyst consensus, the question is whether the recovery thesis the analysts are pricing in will translate into the wider profit margin the restnvest scorecard is waiting to see.
Dive deeper into the fundamentals
See UnitedHealth Group Incorporated's full 6-stage analysis on restnvest →See the full analyst picture
See all 26 analyst price targets on Anachart →